Sign In
Buy PGEN
$3.81
-0.0500 (-1.30%)
At Close: Jun 03, 2026
Precigen (NASDAQ:PGEN) Shares Gap Up on Analyst Upgrade
01:23am, Friday, 27'th Mar 2026
Precigen, Inc. (NASDAQ: PGEN - Get Free Report) gapped up prior to trading on Thursday after Citizens Jmp raised their price target on the stock from $8.00 to $9.00. The stock had previously closed at
Precigen: The Best Potential Blockbuster You've Never Heard Of (Your ENT Has)
01:57pm, Thursday, 26'th Mar 2026
Precigen maintains a Buy rating as Papzimeos' strong launch and FDA approval signal blockbuster potential, with Q1 revenues expected to exceed $18M. PGEN's management guides for cash flow breakeven in
These Analysts Boost Their Forecasts On Precigen Following Q4 Results
12:08pm, Thursday, 26'th Mar 2026
Precigen, Inc. (NASDAQ: PGEN) reported mixed results for the fourth quarter on Wednesday.
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
06:56pm, Wednesday, 25'th Mar 2026
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
06:37pm, Wednesday, 25'th Mar 2026
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.04 per share a year ago.
Precigen Reports Full Year 2025 Financial Results and Business Updates
04:05pm, Wednesday, 25'th Mar 2026
Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS™ (zopapogene imadenovec-drba), the first-and-only FDA-approved treatment for adults with RRP, in August 2025 PAP
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
04:05pm, Wednesday, 11'th Mar 2026
GERMANTOWN, Md., March 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to impro
Precigen, Inc. (NASDAQ:PGEN) Given Average Rating of “Hold” by Brokerages
04:46am, Saturday, 07'th Mar 2026
Shares of Precigen, Inc. (NASDAQ: PGEN - Get Free Report) have been assigned a consensus recommendation of "Hold" from the seven research firms that are covering the stock, Marketbeat.com reports. Two
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech
09:34am, Wednesday, 11'th Feb 2026
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech
Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of “Hold” from Brokerages
04:44am, Tuesday, 10'th Feb 2026
Precigen, Inc. (NASDAQ: PGEN - Get Free Report) has been assigned an average rating of "Hold" from the seven brokerages that are covering the stock, MarketBeat reports. Two analysts have rated the sto
Independent, expert-led consensus paper, sponsored by the Recurrent Respiratory Papillomatosis Foundation, reflects the recommendation of 16 leading physicians in the field of RRP Consensus paper reco
Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
12:55pm, Thursday, 15'th Jan 2026
Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS in August 2025, the first-and-only FDA-approved treatment for adults with RRP PAPZIMEOS commercialization is well
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Monday, 05'th Jan 2026
GERMANTOWN, Md., Jan. 5, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision medicines, today announced that Helen Sabzevari, PhD, President
Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet?
04:38pm, Tuesday, 02'nd Dec 2025
San Diego-based Tang Capital Management initiated new stake: up 12,400,000 shares, an estimated $40.8 million Change represents 1.6% of reportable assets under management Post-trade holding: 12,400,00
